
Visit our Booth and Bispecific ADC Posters at World ADC San Diego: Oct 17-18
Biocytogen’s BD team is excited to exhibit and attend the 14th Annual World ADC San Diego conference, taking place from Oct 17–18, 2023! Be sure…
Read more
Webinar: Predicting Toxicity of Immuno-Oncology Drug Candidates: Preclinical Platforms to Evaluate Toxicology In Vivo and Ex Vivo
Our webinar “Predicting Toxicity of Immuno-Oncology Drug Candidates: Preclinical Platforms to Evaluate Toxicology In Vivo and Ex Vivo" was live at 12:00 PM EDT on Oct…
Read more
Join us at the Festival of Biologics Europe 2023: Oct 10-12
Join us at the Festival of Biologics Europe 2023 in Basel, Switzerland from Oct 10-12! Stop by booth #703 and learn about our preclinical animal…
Read more
Don’t Miss Our Presentation and Booth at BioJapan 2023!
Biocytogen’s Asia-Pacific business development team is pleased to present and exhibit at BioJapan 2023, taking place from October 11-13, 2023 in Yokohama, Japan! Dr. Jie…
Read more
Biocytogen Officially Launches RenMice® Series
Fully Human Antibody and TCR Mouse Models Showcase Biocytogen's Capabilities to Innovate the Discovery of Novel Biologic Drugs Beijing, China, September 15, 2023 – Biocytogen…
Read more
Biocytogen Enters into Antibody Evaluation, Option and License Agreement with Myricx for ADC Development
Beijing, China, September 7, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery of novel antibody…
Read more
Biocytogen Establishes Two Business Divisions to Distinguish Preclinical Models and Services (BioMice) From Antibody Drug R&D
Beijing, China, August 31, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces the official formation of two major business divisions to…
Read more
Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage Antibodies
BEIJING, China, August 30, 2023 – Eucure (Beijing) Biopharma Co., Ltd. (“Eucure”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”), announced today…
Read more
Meet Us at Our Booth in JCA2023!
Biocytogen’s Asia-Pacific business development team is pleased to exhibit at the 82nd annual meeting of the Japanese cancer association, taking place from September 21–23, 2023…
Read more
Biocytogen’s Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth
BEIJING, China--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that its Project Integrum has completed 2 core milestones, and its antibody business is…
Read more